Skin cancers, including melanoma and non-melanoma types, are increasingly recognized as a major public health concern due to their rising incidence and potential for metastasis. Melanoma & Skin Cancers require early detection, accurate diagnosis, and a comprehensive, multidisciplinary approach to treatment. Advances in dermoscopy, imaging technologies, and molecular profiling have enhanced the identification of high-risk lesions and informed personalized treatment strategies. Therapeutic approaches often combine surgical excision, immunotherapy, targeted therapy, and, in select cases, radiation therapy to optimize outcomes. Collaboration among dermatologists, surgical oncologists, medical oncologists, and supportive care teams is essential to address both clinical outcomes and the overall quality of life for patients.
The landscape of Melanoma & Skin Cancers is rapidly evolving with the integration of novel immunotherapies, checkpoint inhibitors, and targeted agents, significantly improving survival for patients with advanced disease. Molecular diagnostics and biomarker testing allow clinicians to select therapies most likely to achieve favorable responses, while adjuvant and neoadjuvant strategies help reduce recurrence risk. Supportive care, patient education, and survivorship planning are critical for managing side effects and promoting long-term well-being. By combining precision medicine, innovative therapies, and multidisciplinary care, melanoma and skin oncology continues to advance, offering patients more effective, individualized, and durable treatment options while enhancing overall quality of life.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation